Intrauterine Drug Delivery Systems

Intravaginal drug delivery systems bypass first-pass metabolism, which occurs when drugs are absorbed through the gastrointestinal tract and processed by the liver before reaching systemic circulation. By delivering hormones directly through the vaginal mucosa, these systems enhance bioavailability and allow for reduced systemic dosages. This route improves therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.

Intravaginal systems include matrix diffusion-controlled devices, such as medroxyprogesterone acetate dispersed in silicone elastomer, and dissolution-controlled systems where progestins and estrogens are dispersed in polyethylene glycol and silicone matrices. The most common formulation is the vaginal ring, manufactured by extruding the drug-silicone composition into a doughnut shape. These rings typically release hormones for approximately 21 days, maintaining cyclic hormonal profiles for contraceptive efficacy.

Copper IUDs are T- or 7-shaped plastic devices with copper wire wound around the frame. When inserted, the copper gradually oxidizes in body fluids and releases copper ions locally within the uterus. These ions exert a cytotoxic effect on sperm, preventing fertilization. With a surface area of approximately 200 mm², copper IUDs remain effective for over three years.

Progesterone-releasing IUDs are T-shaped devices containing a reservoir of progesterone dispersed in a silicone matrix. The hormone is released through a rate-controlling ethylene-vinyl acetate copolymer membrane at a daily dose of approximately 65 micrograms. This design ensures sustained hormone delivery and consistent contraceptive action for up to one year.

Vaginal rings provide sustained hormone release for approximately 21 days, offering cyclic intravaginal contraception that requires regular replacement. In contrast, intrauterine devices offer extended protection: copper IUDs remain effective for over three years, while progesterone-releasing IUDs provide contraceptive action for up to one year. These differences allow patients to choose based on their preferred contraceptive duration.

Silicone and polyethylene glycol are used as matrix materials in intravaginal delivery systems because they enable controlled drug release through diffusion and dissolution mechanisms. Silicone elastomer provides a stable, biocompatible polymer that allows medroxyprogesterone acetate to diffuse gradually, while PEG-silicone combinations support dissolution-controlled release of progestins and estrogens. These materials ensure sustained, predictable hormone delivery over the desired therapeutic period.

Intrauterine devices provide extended contraceptive effectiveness, typically exceeding 12 months and lasting up to several years depending on device type. Unlike oral contraceptives requiring daily dosing, IUDs eliminate compliance issues through localized hormone delivery or copper ion release. They offer both short- and long-term options: copper IUDs for extended protection and progesterone-releasing IUDs for moderate-duration contraception with minimal systemic hormone exposure.